RxDoctor Payments Data

Hubert Chow, MD

Family Medicine · San Gabriel, CANPI 1669697686

Payments from drug & device makers

$1,976in general payments, 2019–2025

Across 60 payments — averaging $32.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$340
  • Medtronic$144
  • Abbott$135
  • GSK$125
  • Boehringer Ingelheim$113

What the payments were for

  • Food & beverage$1,976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk35$1,119
Amgen21$340
Medtronic1$144
Abbott1$135
GSK1$125
Boehringer Ingelheim1$113

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,976 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$19,319
Medicare patients
54
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide35$61,871
ProliaDenosumab22$36,384
Cyclosporine31$26,306
OzempicSemaglutide23$22,967
VascepaIcosapent Ethyl35$17,222
RestasisCyclosporine11$8,328
FarxigaDapagliflozin Propanediol12$6,641
Atorvastatin Calcium301$2,572
Omega-3 Acid Ethyl Esters38$2,423
Losartan Potassium252$2,202
Nifedipine ErNifedipine67$1,948
Rosuvastatin Calcium105$1,798
Tamsulosin Hcl96$1,529
Metformin Hcl159$1,028
Levothyroxine Sodium73$872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,119$84,83858 claims
AmgenProlia$340$36,38422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in San Gabriel

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →